Gastrointestinalis stroma tumorok (GISTs): Klinikai és patológiai jellemzok

Translated title of the contribution: Gastrointestinal stromal tumors (GISTs): Clinical and pathological features

Márta Kovács, Pál Nagy, Gábor Pák, J. Fehér

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. With immunohistochemical, electron microscope and molecular examinations they can be clearly distinguished in both their genotype and fenotype from other mesenchymal tumors. GIST tumors express the CD 117 receptor in more than 90% independent of histopathological features and clinical behaviour. This is why it is considered as the most important characteristic. The incidence is 10-20 new cases per 1 million annually. The number of incidents is expected to increase by the establishment of CD117 and other new markers (protein kinase C theta, DOG1). Nowadays the establishment of the expected biological behavior and malignancy can be difficult. The best prognostic factors are the tumor size and the mitotic index. Dominantly, due to the mutation of the c-kit proto-oncogen and PGDFRA gene that the high level tyrosine kinase activity generates resulting uncontrolled proliferation and cell growth. The imatinib mesylate is a selective inhibitor of the KIT tyrosine kinase receptor and it also blocks the activity of the PDGFRA kinase. The therapeutic consequence of this is that the majority of advanced GIST tumors which do not react to conventional radio- and chemotherapy respond well to tyrosine kinase inhibitor treatment. As a result, survival and patient's quality of life can significantly improve.

Original languageHungarian
Pages (from-to)1375-1381
Number of pages7
JournalOrvosi Hetilap
Volume146
Issue number26
Publication statusPublished - 2005

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Protein-Tyrosine Kinases
Mitotic Index
Receptor Protein-Tyrosine Kinases
Carcinogens
Protein Kinase C
Gastrointestinal Tract
Phosphotransferases
Radiotherapy
Genotype
Quality of Life
Cell Proliferation
Electrons
Drug Therapy
Mutation
Survival
Incidence
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gastrointestinalis stroma tumorok (GISTs) : Klinikai és patológiai jellemzok. / Kovács, Márta; Nagy, Pál; Pák, Gábor; Fehér, J.

In: Orvosi Hetilap, Vol. 146, No. 26, 2005, p. 1375-1381.

Research output: Contribution to journalArticle

Kovács, M, Nagy, P, Pák, G & Fehér, J 2005, 'Gastrointestinalis stroma tumorok (GISTs): Klinikai és patológiai jellemzok', Orvosi Hetilap, vol. 146, no. 26, pp. 1375-1381.
Kovács, Márta ; Nagy, Pál ; Pák, Gábor ; Fehér, J. / Gastrointestinalis stroma tumorok (GISTs) : Klinikai és patológiai jellemzok. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 26. pp. 1375-1381.
@article{0b658e0f47d440509942b449e016719e,
title = "Gastrointestinalis stroma tumorok (GISTs): Klinikai {\'e}s patol{\'o}giai jellemzok",
abstract = "The gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. With immunohistochemical, electron microscope and molecular examinations they can be clearly distinguished in both their genotype and fenotype from other mesenchymal tumors. GIST tumors express the CD 117 receptor in more than 90{\%} independent of histopathological features and clinical behaviour. This is why it is considered as the most important characteristic. The incidence is 10-20 new cases per 1 million annually. The number of incidents is expected to increase by the establishment of CD117 and other new markers (protein kinase C theta, DOG1). Nowadays the establishment of the expected biological behavior and malignancy can be difficult. The best prognostic factors are the tumor size and the mitotic index. Dominantly, due to the mutation of the c-kit proto-oncogen and PGDFRA gene that the high level tyrosine kinase activity generates resulting uncontrolled proliferation and cell growth. The imatinib mesylate is a selective inhibitor of the KIT tyrosine kinase receptor and it also blocks the activity of the PDGFRA kinase. The therapeutic consequence of this is that the majority of advanced GIST tumors which do not react to conventional radio- and chemotherapy respond well to tyrosine kinase inhibitor treatment. As a result, survival and patient's quality of life can significantly improve.",
keywords = "c-kit gene mutation, CD 117 expression, GIST, Immunohistochemistry, Tyrosine kinase inhibition",
author = "M{\'a}rta Kov{\'a}cs and P{\'a}l Nagy and G{\'a}bor P{\'a}k and J. Feh{\'e}r",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1375--1381",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "26",

}

TY - JOUR

T1 - Gastrointestinalis stroma tumorok (GISTs)

T2 - Klinikai és patológiai jellemzok

AU - Kovács, Márta

AU - Nagy, Pál

AU - Pák, Gábor

AU - Fehér, J.

PY - 2005

Y1 - 2005

N2 - The gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. With immunohistochemical, electron microscope and molecular examinations they can be clearly distinguished in both their genotype and fenotype from other mesenchymal tumors. GIST tumors express the CD 117 receptor in more than 90% independent of histopathological features and clinical behaviour. This is why it is considered as the most important characteristic. The incidence is 10-20 new cases per 1 million annually. The number of incidents is expected to increase by the establishment of CD117 and other new markers (protein kinase C theta, DOG1). Nowadays the establishment of the expected biological behavior and malignancy can be difficult. The best prognostic factors are the tumor size and the mitotic index. Dominantly, due to the mutation of the c-kit proto-oncogen and PGDFRA gene that the high level tyrosine kinase activity generates resulting uncontrolled proliferation and cell growth. The imatinib mesylate is a selective inhibitor of the KIT tyrosine kinase receptor and it also blocks the activity of the PDGFRA kinase. The therapeutic consequence of this is that the majority of advanced GIST tumors which do not react to conventional radio- and chemotherapy respond well to tyrosine kinase inhibitor treatment. As a result, survival and patient's quality of life can significantly improve.

AB - The gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. With immunohistochemical, electron microscope and molecular examinations they can be clearly distinguished in both their genotype and fenotype from other mesenchymal tumors. GIST tumors express the CD 117 receptor in more than 90% independent of histopathological features and clinical behaviour. This is why it is considered as the most important characteristic. The incidence is 10-20 new cases per 1 million annually. The number of incidents is expected to increase by the establishment of CD117 and other new markers (protein kinase C theta, DOG1). Nowadays the establishment of the expected biological behavior and malignancy can be difficult. The best prognostic factors are the tumor size and the mitotic index. Dominantly, due to the mutation of the c-kit proto-oncogen and PGDFRA gene that the high level tyrosine kinase activity generates resulting uncontrolled proliferation and cell growth. The imatinib mesylate is a selective inhibitor of the KIT tyrosine kinase receptor and it also blocks the activity of the PDGFRA kinase. The therapeutic consequence of this is that the majority of advanced GIST tumors which do not react to conventional radio- and chemotherapy respond well to tyrosine kinase inhibitor treatment. As a result, survival and patient's quality of life can significantly improve.

KW - c-kit gene mutation

KW - CD 117 expression

KW - GIST

KW - Immunohistochemistry

KW - Tyrosine kinase inhibition

UR - http://www.scopus.com/inward/record.url?scp=24144474317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144474317&partnerID=8YFLogxK

M3 - Article

C2 - 16052979

AN - SCOPUS:24144474317

VL - 146

SP - 1375

EP - 1381

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 26

ER -